Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Hongwei Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8620-3842; OpenAlex author ID A5054416550. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2020: 3 papers · 2021: 7 papers · 2022: 7 papers · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 19

  1. Temporal trends in cross-country inequalities of early-onset pancreatic cancer: a comprehensive analysis for the global burden of disease study 2021. Last author DOI 10.1038/s41598-025-93892-8↗
  2. IGF2BP2-related modification patterns in pancreatic cancer: A machine learning-driven approach towards personalized treatment. Co-author DOI 10.1016/j.heliyon.2024.e28243↗
  3. The NF-κB/miR-488/ERBB2 axis modulates pancreatic cancer cell malignancy and tumor growth through cell cycle signaling. Co-author DOI 10.1080/15384047.2022.2054257↗
  4. Identification of EMT-Related lncRNAs as Potential Prognostic Biomarkers and Therapeutic Targets for Pancreatic Adenocarcinoma. Co-author DOI 10.1155/2022/8259951↗
  5. Risk factors and prognostic index model for pancreatic cancer. Co-author DOI 10.21037/gs-21-848↗
  6. Impact of the tumor immune microenvironment on the outcome of pancreatic cancer: a retrospective study based on clinical pathological analysis. Co-author DOI 10.21037/gs-22-45↗
  7. Ferroptosis-Related IncRNAs Are Prognostic Biomarker of Overall Survival in Pancreatic Cancer Patients. Co-author DOI 10.3389/fcell.2022.819724↗
  8. Interplay of four types of RNA modification writers revealed distinct tumor microenvironment and biological characteristics in pancreatic cancer. Co-author DOI 10.3389/fimmu.2022.1031184↗
  9. DSCR9/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling. Co-author DOI 10.3724/abbs.2022194↗
  10. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.01.011↗
  11. PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001747↗
  12. Wogonoside inhibits TNF receptor-associated factor 6 (TRAF6) mediated-tumor microenvironment and prognosis of pancreatic cancer. Co-author DOI 10.21037/atm-21-4164↗
  13. Expressional and Prognostic Value of S100A16 in Pancreatic Cancer Via Integrated Bioinformatics Analyses. Last author DOI 10.3389/fcell.2021.645641↗
  14. NR2F1-AS1 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Competing Endogenous RNA Regulatory Network Constructed by Sponging miRNA-146a-5p/miRNA… Co-author DOI 10.3389/fcell.2021.736980↗
  15. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.728062↗
  16. m6A-Mediated Upregulation of LINC00857 Promotes Pancreatic Cancer Tumorigenesis by Regulating the miR-150-5p/E2F3 Axis. Last author DOI 10.3389/fonc.2021.629947↗
  17. Autophagy Regulatory Genes MET and RIPK2 Play a Prognostic Role in Pancreatic Ductal Adenocarcinoma: A Bioinformatic Analysis Based on GEO and TCGA. Co-author DOI 10.1155/2020/8537381↗
  18. Multiomics integrative analysis for gene signatures and prognostic values of m6A regulators in pancreatic adenocarcinoma: a retrospective study in The Cancer G… Last author DOI 10.18632/aging.103942↗
  19. CircHIPK3 Promotes Gemcitabine (GEM) Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1. Last author DOI 10.2147/cmar.s239326↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenzhe Gao · 11 shared papers, 2020–2025 · strength 1.87
  2. Xiao Yu · 6 shared papers, 2020–2022 · strength 0.91
  3. Longjun Zang · 4 shared papers, 2021–2024 · strength 0.70
  4. Dongjie Chen · 4 shared papers, 2021–2024 · strength 0.70
  5. Yunfei Liu · 4 shared papers, 2020–2022 · strength 0.60
  6. Xiao Yu · 4 shared papers, 2020–2024 · strength 0.60
  7. Xiao Yu · 2 shared papers, 2021–2022 · strength 0.35
  8. Yanyao Deng · 2 shared papers, 2021–2022 · strength 0.34
  9. Hui Huang · 2 shared papers, 2021–2022 · strength 0.33
  10. Duo Han · 2 shared papers, 2022 · strength 0.31
  11. Luohong Li · 1 shared paper, 2025 · strength 0.30
  12. Xiao Yu · 1 shared paper, 2022 · strength 0.17
  13. Xiao Li Yu · 1 shared paper, 2022 · strength 0.17
  14. Hui Ling Huang · 1 shared paper, 2022 · strength 0.17
  15. Dong Luo · 1 shared paper, 2021 · strength 0.17
  16. Xiangrui Meng · 1 shared paper, 2021 · strength 0.17
  17. Shuai Wang · 1 shared paper, 2022 · strength 0.16
  18. Jixing Liu · 1 shared paper, 2022 · strength 0.16
  19. Xingyu Li · 1 shared paper, 2020 · strength 0.16
  20. Zhiqiang Li · 1 shared paper, 2020 · strength 0.16
  21. Yun-Fei Liu · 1 shared paper, 2021 · strength 0.16
  22. Xiao Yu · 1 shared paper, 2022 · strength 0.15
  23. Hui Huang · 1 shared paper, 2022 · strength 0.15
  24. Guangping Tu · 1 shared paper, 2021 · strength 0.14
  25. Hui Huang · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.